Litcius/Paper detail

Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real‐life study

Angelo Ruggiero, Luca Potestio, Sara Cacciapuoti, Lucia Gallo, Teresa Battista, Elisa Camela, Gabriella Fabbrocini, Matteo Megna

2022Dermatologic Therapy39 citationsDOI

Topics & Concepts

MedicineSection (typography)PsoriasisDermatologyAdvertisingBusinessPsoriasis: Treatment and PathogenesisDermatology and Skin DiseasesAutoimmune Bullous Skin Diseases
Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real‐life study | Litcius